Provided by Tiger Fintech (Singapore) Pte. Ltd.

Checkpoint Therapeutics, Inc.

4.12
+0.0000
Volume:899.70K
Turnover:3.71M
Market Cap:345.11M
PE:-2.91
High:4.14
Open:4.10
Low:4.10
Close:4.12
Loading ...

Checkpoint Therapeutics initiated with a Buy at D. Boral Capital

TIPRANKS
·
13 Jan

Unusually active option classes on open December 16th

TIPRANKS
·
16 Dec 2024

Checkpoint Therapeutics Shares Rise 5.7% After US FDA Approves Co's Skin Cancer Drug

THOMSON REUTERS
·
16 Dec 2024

FDA Approves Checkpoint Therapeutics' Skin Cancer Drug One Year After Rejection

Benzinga
·
16 Dec 2024

Pre-Bell|U.S. Futures Rise; Tesla Gains 1%; Broadcom and MicroStrategy Jump 3%; Super Micro Plunges 13%

Tiger Newspress
·
16 Dec 2024

Checkpoint Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.

Dow Jones
·
16 Dec 2024

Analysts Offer Insights on Healthcare Companies: Checkpoint Therapeutics (CKPT) and Roche Holding AG (OtherRHHVF)

TIPRANKS
·
16 Dec 2024

BUZZ-Checkpoint Therapeutics rises after FDA approval of co's skin cancer drug

Reuters
·
16 Dec 2024

Checkpoint Therapeutics Shares Rise 9.3% Premarket After US FDA Approves Co's Skin Cancer Drug

THOMSON REUTERS
·
16 Dec 2024

Checkpoint Therapeutics' Shares Rise After Securing First FDA Approval

Dow Jones
·
14 Dec 2024

Checkpoint Therapeutics trading resumes

TIPRANKS
·
14 Dec 2024

Checkpoint Therapeutics confirms FDA approval of unloxcyt

TIPRANKS
·
14 Dec 2024

Checkpoint Therapeutics Gets Its First FDA Approval

Dow Jones
·
14 Dec 2024

BRIEF-Checkpoint Therapeutics Announces FDA Approval Of Unloxcyt (Cosibelimab-Ipdl)

Reuters
·
14 Dec 2024

US FDA approves Checkpoint's skin cancer drug

Reuters
·
14 Dec 2024

FDA Approves Cosibelimab-Ipdl for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma - Website

THOMSON REUTERS
·
14 Dec 2024

FDA: Approval of Cosibelimab-Ipdl (Unloxcyt) Granted to Checkpoint Therapeutics

THOMSON REUTERS
·
14 Dec 2024

Checkpoint Therapeutics trading halted, news pending

TIPRANKS
·
14 Dec 2024

Checkpoint Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.

Dow Jones
·
04 Dec 2024

Checkpoint Therapeutics Third Quarter 2024 Earnings: US$0.23 loss per share (vs US$0.29 loss in 3Q 2023)

Simply Wall St.
·
15 Nov 2024